File Download
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1186/s12943-020-01197-3
- Scopus: eid_2-s2.0-85084107503
- PMID: 32340605
- WOS: WOS:000530432500001
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Epigenetic regulation in human cancer: the potential role of epi-drug in cancer therapy
Title | Epigenetic regulation in human cancer: the potential role of epi-drug in cancer therapy |
---|---|
Authors | |
Keywords | Epigenetic modification Cancer Epi-drugs Combination strategy Tumour microenvironment |
Issue Date | 2020 |
Publisher | BioMed Central Ltd. The Journal's web site is located at http://www.molecular-cancer.com |
Citation | Molecular Cancer, 2020, v. 19 n. 1, p. article no. 79 How to Cite? |
Abstract | Epigenetics is dynamic and heritable modifications to the genome that occur independently of DNA sequence. It requires interactions cohesively with various enzymes and other molecular components. Aberrant epigenetic alterations can lead to inappropriate onset of genetic expressions and promote tumorigenesis. As the epigenetic modifiers are susceptible to extrinsic factors and reversible, they are becoming promising targets in multiple cancer therapies. Recently, various epi-drugs have been developed and implicated in clinical use. The use of epi-drugs alone, or in combination with chemotherapy or immunotherapy, has shown compelling outcomes, including augmentation of anti-tumoral effects, overcoming drug resistance, and activation of host immune response. |
Description | eid_2-s2.0-85084107503 |
Persistent Identifier | http://hdl.handle.net/10722/282546 |
ISSN | 2023 Impact Factor: 27.7 2023 SCImago Journal Rankings: 8.222 |
PubMed Central ID | |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | LU, Y | - |
dc.contributor.author | Chan, Y-T | - |
dc.contributor.author | Tan, H-Y | - |
dc.contributor.author | Li, S | - |
dc.contributor.author | Wang, N | - |
dc.contributor.author | Feng, Y | - |
dc.date.accessioned | 2020-05-15T05:29:30Z | - |
dc.date.available | 2020-05-15T05:29:30Z | - |
dc.date.issued | 2020 | - |
dc.identifier.citation | Molecular Cancer, 2020, v. 19 n. 1, p. article no. 79 | - |
dc.identifier.issn | 1476-4598 | - |
dc.identifier.uri | http://hdl.handle.net/10722/282546 | - |
dc.description | eid_2-s2.0-85084107503 | - |
dc.description.abstract | Epigenetics is dynamic and heritable modifications to the genome that occur independently of DNA sequence. It requires interactions cohesively with various enzymes and other molecular components. Aberrant epigenetic alterations can lead to inappropriate onset of genetic expressions and promote tumorigenesis. As the epigenetic modifiers are susceptible to extrinsic factors and reversible, they are becoming promising targets in multiple cancer therapies. Recently, various epi-drugs have been developed and implicated in clinical use. The use of epi-drugs alone, or in combination with chemotherapy or immunotherapy, has shown compelling outcomes, including augmentation of anti-tumoral effects, overcoming drug resistance, and activation of host immune response. | - |
dc.language | eng | - |
dc.publisher | BioMed Central Ltd. The Journal's web site is located at http://www.molecular-cancer.com | - |
dc.relation.ispartof | Molecular Cancer | - |
dc.rights | Molecular Cancer. Copyright © BioMed Central Ltd. | - |
dc.rights | This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. | - |
dc.subject | Epigenetic modification | - |
dc.subject | Cancer | - |
dc.subject | Epi-drugs | - |
dc.subject | Combination strategy | - |
dc.subject | Tumour microenvironment | - |
dc.title | Epigenetic regulation in human cancer: the potential role of epi-drug in cancer therapy | - |
dc.type | Article | - |
dc.identifier.email | Chan, Y-T: ecyt1@hku.hk | - |
dc.identifier.email | Tan, H-Y: hyhtan@hku.hk | - |
dc.identifier.email | Li, S: lishaha@hku.hk | - |
dc.identifier.email | Wang, N: ckwang@hku.hk | - |
dc.identifier.email | Feng, Y: yfeng@hku.hk | - |
dc.identifier.authority | Wang, N=rp02075 | - |
dc.identifier.authority | Feng, Y=rp00466 | - |
dc.description.nature | published_or_final_version | - |
dc.identifier.doi | 10.1186/s12943-020-01197-3 | - |
dc.identifier.pmid | 32340605 | - |
dc.identifier.pmcid | PMC7184703 | - |
dc.identifier.scopus | eid_2-s2.0-85084107503 | - |
dc.identifier.hkuros | 309972 | - |
dc.identifier.volume | 19 | - |
dc.identifier.issue | 1 | - |
dc.identifier.spage | article no. 79 | - |
dc.identifier.epage | article no. 79 | - |
dc.identifier.isi | WOS:000530432500001 | - |
dc.publisher.place | United Kingdom | - |
dc.identifier.issnl | 1476-4598 | - |